Influence of sociodemographic variables and tobacco consumption on the risk of nonalcoholic fatty liver disease and liver fibrosis

• Liliana Laird ^[1] ; Cristina Núñez Fernández ^[2] ; María Gil Llinás ^[3] ; Rosa González Casquero ^[3] ; Irene del Rocío Campos González ^[3]
  1. [1] Aesthetica Edinburgh. Scotland
  2. [2] Clínica Aureo. Palma. Balearic Islands. Spain
  3. [3] Occupational Health Service of Balearic Health Service

  Mostrar afiliaciones +
• Localización: Academic Journal of Health Sciences: Medicina Balear, ISSN-e 2255-0560, Vol. 36, Nº. 3, 2021, págs. 34-39
• Idioma: inglés
• DOI: 10.3306/AJHS.2021.36.03.34
• Títulos paralelos:
  • Influencia de las variables sociodemográficas y del consumo de tabaco en el riesgo de padecer hígado graso no alcohólico y fibrosis hepática
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    Introducción: El hígado graso no alcohólico (NAFLD) es la principal causa de enfermedad hepática en el mundo occidental. Aunque es normal tener una cantidad determinada de grasa en el hígado, cuando ésta supera el 10% se convierte en un problema de salud. No suele ser una enfermedad grave, a no ser que se acompañe de esteatohepatitis (inflamación del hígado causado por la presencia de grasa), lo que puede evolucionar en cirrosis y/o cáncer hepático.

    Material y métodos: Se realizó un estudio descriptivo y transversal en 9,550 usuarios del Sistema Nacional de Salud de Escocia en los que se valoró la influencia de variables sociodemográficas como edad, sexo y nivel de estudios y, el consumo de tabaco en la prevalencia de Hígado graso no alcohólico y fibrosis hepática determinados con diferentes escalas.

    Resultados: La prevalencia de alto riesgo de NAFLD y fibrosis hepática determinada mediante escalas de riesgo se ve influenciada por el sexo (más prevalente en hombres), edad (va incrementándose con la edad), nivel de estudios (mayor prevalencia en las personas con menores estudios) y consumo de tabaco (algo más prevalente en los fumadores aunque sólo con el hepatic steatosis index).

    Conclusiones: Los valores de alto riesgo en las escalas de NAFLD y fibrosis hepática se ven influidos por las variables sociodemográficas y solo en algunos casos por el consumo de tabaco.

  • English

    Introduction: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in the Western world. Although it is normal to have a certain amount of fat in the liver, when it exceeds 10% it becomes a health problem. It is not usually a serious disease, unless it is accompanied by steatohepatitis (inflammation of the liver caused by the presence of fat), which can develop into cirrhosis and/or liver cancer.

    Methods: A descriptive and cross-sectional study was carried out in 9,550 users of the Scottish National Health System in which the influence of sociodemographic variables such as age, sex and educational level and tobacco consumption on the prevalence of non-alcoholic fatty liver disease and liver fibrosis determined with different scales was assessed.

    Results: The prevalence of high risk of NAFLD and liver fibrosis determined by risk scales is influenced by sex (more prevalent in men), age (increasing with age), educational level (higher prevalence in people with less education) and tobacco use (somewhat more prevalent in smokers, although only with the hepatic steatosis index).

    Conclusions: The high-risk values in the NAFLD and hepatic fibrosis scales are influenced by sociodemographic variables and only in some cases by tobacco consumption.

• Referencias bibliográficas
  • Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-31
  • Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic...
  • Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic...
  • Caballería L, Pera G, Auladell MA, Torán P, Muñoz L, Miranda D, et al. Prevalence and factors associated with the presence of nonalcoholic...
  • Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155-61.
  • Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease:...
  • Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic...
  • Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012 Feb;32(1):22-9....
  • Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y...
  • Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med (Lond). 2011 Apr;11(2):176-8
  • Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty...
  • Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004 Jul;114(2):147-52
  • Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol. 2006 Feb;44(2):253-61.
  • Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab. 2012 May 2;15(5):574-84....
  • Chiang JK, Koo M. Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in Taiwanese people...
  • Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple...
  • Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic...
  • Wang J, Xu C, Xun Y, Lu Z,Shi J, Yu Ch, et al. ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese...
  • Fuyan S, Jing L, Wenjun C, Zhijun T, Weijing M, Suzhen W, et al. Fatty liver disease index: a simple screening tool to facilitate...
  • Long MT, Pedley A, Colantonio LD, Massaro JM, Hoffmann U, Muntner P, Fox CS. Development and Validation of the Framingham...
  • Raszeja-Wyszomirska J, Szymanik B, Ławniczak M, Kajor M, Chwist A, Milkiewicz P, et al. Validation of the BARD scoring ...
  • Shima T, Seki K, Umemura A, Ogawa R, Horimoto R, Oya H, et al. Influence of lifestyle-related diseases and age on the...
  • Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD)...
  • Hu X-Y, Li Y, Li L-Q, Zheng Y, Lu J-H, Huang S-Cet al. Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational...
  • Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155-61. (art...
  • Jia G, Li X, Wang L, Li Q, Yang L, Li N, Di F. Relationship of socioeconomic status and non-alcoholic fatty liver disease...
  • Cho J, Lee I, Park DH, Kwak HB, Min K. Relationships between Socioeconomic Status, Handgrip Strength, and NonAlcoholic Fatty Liver...
  • Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of Nonalcoholic Fatty Liver Disease and Economy. Dig Dis ...
  • Orkin S, Brokamp C, Yodoshi T, Trout AT, Liu C, Meryum S, et al. Community Socioeconomic Deprivation and Nonalcoholic Fatty Liver Disease...
  • Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, Shin H, Ryu S. Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study....
  • Kim NH, Jung YS, Hong HP, Park JH, Kim HJ, Park DI, et al. Association between cotinine-verified smoking status and risk of...
  • Liu Y, Dai M, Bi Y, Xu M, Xu Y, Li M, Wang T, Huang F, Xu B, Zhang J, Li X, Wang W, Ning G. Active smoking, passive smoking, and risk of nonalcoholic...